| Multiply resistant Klebsiella pneumoniae strains from two Chicago hospitals: identification of the extended-spectrum TEM-12 and TEM-10 ceftazidime-hydrolyzing beta-lactamases … PA Bradford, CE Cherubin, V Idemyor, BA Rasmussen, K Bush Antimicrobial agents and chemotherapy 38 (4), 761-766, 1994 | 200 | 1994 |
| Human immunodeficiency virus (HIV) and malaria interaction in sub-Saharan Africa: the collision of two Titans V Idemyor HIV clinical trials 8 (4), 246-253, 2007 | 76 | 2007 |
| Diabetes in sub-Saharan Africa: health care perspectives, challenges, and the economic burden of disease V Idemyor Journal of the National Medical Association 102 (7), 650-653, 2010 | 67 | 2010 |
| HIV and tuberculosis coinfection: inextricably linked liaison. V Idemyor Journal of the National Medical Association 99 (12), 1414, 2007 | 57 | 2007 |
| Lassa virus infection in Nigeria: Clinical perspective overview I Vincent Journal of the National Medical Association 102 (12), 1243-1246, 2010 | 21 | 2010 |
| Human immunodeficiency virus (HIV) entry inhibitors (CCR5 specific blockers) in development: are they the next novel therapies? V Idemyor HIV Clinical Trials 6 (5), 272-277, 2005 | 21 | 2005 |
| The 2004 International AIDS Conference and how to globally counter HIV/AIDS V Idemyor HIV Clinical Trials 6 (1), 43-49, 2005 | 13 | 2005 |
| Emerging opportunistic fungal infections: where are we heading? V Idemyor Journal of the National Medical Association 95 (12), 1211, 2003 | 13 | 2003 |
| Pleurocerebral Nocardia in a Patient with Human Immunodeficiency Virus V Idemyor, CE Cherubin Annals of Pharmacotherapy 26 (2), 188-189, 1992 | 13 | 1992 |
| Continuing debate over HIV therapy initiation V Idemyor HIV Clinical Trials 3 (2), 173-176, 2002 | 12 | 2002 |
| Human immunodeficiency virus: scientific challenges impeding candidate vaccines V Idemyor HIV clinical trials 4 (6), 421-424, 2003 | 9 | 2003 |
| Human immunodeficiency viruses and drug therapy: resistance and implications for antiretroviral therapy V Idemyor Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy 22 (5 …, 2002 | 7 | 2002 |
| Genomic medicine: health care issues and the unresolved ethical and social dilemmas V Idemyor American Journal of Therapeutics 21 (6), 548-553, 2014 | 6 | 2014 |
| Promising microbicide approach for prevention of human immunodeficiency virus transmission needs more support V Idemyor Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy 22 (8 …, 2002 | 6 | 2002 |
| The concept of structured treatment interruptions in the management of patients with human immunodeficiency virus (HIV) disease: where are we currently? I Vincent HIV Clinical Trials 4 (2), 79-83, 2003 | 5 | 2003 |
| 20 Years since human immunodeficiency virus discovery: Considerations for the next decade V Idemyor Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy 23 (3 …, 2003 | 5 | 2003 |
| Rapidly progressing mesothelioma in an HIV-positive patient V Idemyor, CE Cherubin Annals of Pharmacotherapy 26 (3), 429-429, 1992 | 5 | 1992 |
| Biological Warfare—A Growing Healthcare Concern V Idemyor, SW Smith Annals of Pharmacotherapy 36 (7-8), 1282-1286, 2002 | 4 | 2002 |
| Retroperitoneal abscess caused by Mycobacterium chelonae and treatment V Idemyor, CE Cherubin Annals of Pharmacotherapy 27 (2), 178-179, 1993 | 4 | 1993 |
| The role of Multinational Oil Companies in Nigerian Federation V Idemyor Indigenous affairs, 56-61, 1999 | 3 | 1999 |
